Skip to content

Effectiveness of nutraceutical therapies on symptoms in adults with long-COVID-19: The Alliance Long COVID-19 Treatment Trial

Development of a 2-stage nutraceutical treatment protocol for adults with long-COVID-19 syndrome, exploring underlying pathophysiology and treatment effectiveness

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12622001204730
Enrollment
60
Registered
2022-09-08
Start date
2022-10-24
Completion date
2022-12-21
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A large number of people experience long-COVID Symptoms persisting for weeks and months after overcoming the acute illness. Symptoms include chronic fatigue, breathlessness, muscle pain, persistent cough, loss of sense of smell and/or taste. This study aims to explore underlying disease etiology by a series of blood tests and clinical assessment, followed by a staged treatment approach of 2x 6 weeks. After clinical assessment by a trial doctor, eligible participants will receive intervention-1 for a 6-week period, and allocated to one of three groups of intervention in the 2nd 6-week period. This study is exploratory, and will provide important insights for protocol development for a larger cohort study.

Interventions

2-staged intervention after baseline and 6 week assessments: Stage 1 (1-6th week): 6 week nutritional supplement consisting of 35g pineapple powder + 2x3g ginger infused oil per day to be consumed at meal-times with food as convenient; adherence monitored by diary Stage 2 (7-12th week): 3 groups: Allocation by location and referral by the trial doctor. Group 1 will receive 30g of Intravenous Vitamin C twice weekly for 6 weeks, administered by a registered nurse, Group 2 will receive all of the

2-staged intervention after baseline and 6 week assessments: Stage 1 (1-6th week): 6 week nutritional supplement consisting of 35g pineapple powder + 2x3g ginger infused oil per day to be consumed at meal-times with food as convenient; adherence monitored by diary Stage 2 (7-12th week): 3 groups: Allocation by location and referral by the trial doctor. Group 1 will receive 30g of Intravenous Vitamin C twice weekly for 6 weeks, administered by a registered nurse, Group 2 will receive all of the following oral supplements as capsules [Kyolic aged garlic extract (1.2 g) + Fish oil (2g) + Curcumin (500mg) + N-acetylcysteine (600mg) + Vitamin D (5000 IU) + Vitamin C (1g) + Zinc (15mg)] daily for 6 weeks, administered by the principal investigator; adherence will be monitored by return of unused supplements at the end of the 6 week period Group 3 will continue to receive the nutritional supplement consisting of 35g pineapple powder + 2x3g ginger infused oil per day to be consumed with food at meal-times as convenient for 6 weeks; adherence monitored by diary

Sponsors

AProf Dr Karin Ried
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Other
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Had COVID-19, evident by PCR or RAT, more than 3 months ago Persistent symptoms longer than 3 months Referred to and assessed by trial doctor as suitable for the trial

Exclusion criteria

not able to provide consent Major illness requiring medical intervention and/or hospitalisation

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026